30 closest matches · ranked by relevance
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Vasculitis · Wegener's Granulomatosis · Microscopic Polyangiitis
Primary: Disease Remission — 63; 52 Participants — p=<0.001
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Non-Hodgkin Lymphoma · Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL)…
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Incidence Rate of Serious Infections — 7.11 events per 100 patient year
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed
Granulomatosis With Polyangiitis
Primary: Percentage of Participants With Adverse Events (AEs), Including Serious AEs — 100; 100; 28; 48 percentage of participants
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Wegener's Granulomatosis
Primary: Remission of Vasculitis — 95 Percentage of participants
Lymphoma · Hodgkin Lymphoma (Category) · Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Progression-free Survival (PFS) — 18 participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Epstein-Barr Virus-Associated Lymphoma · Lymphoproliferative Disorders
Primary: Number (Proportion) of Participants With Adverse Events (AEs) — 7; 5; 4; 4 Participants
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Lymphoma
Primary: Complete Response Rate — 23 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Recurrent Grade 1 Follicular Lymphoma · Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 3 Follicular Lymphoma
Primary: Response Rate — 11; 6 participants
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Lymphoma
Primary: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events — 52 Participants
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants